Abbott Laboratories (ABT +0.5%) announces that studies of its experimental hepatitis C drug...

Abbott Laboratories (ABT +0.5%) announces that studies of its experimental hepatitis C drug showed it suppressed the virus in most patients. If further studies follow through with positive results, the company plans to launch a new hepatitis C regimen in 2015.